KR20220121838A - 인테그린 억제제를 사용한 간 질환의 조합 치료 - Google Patents

인테그린 억제제를 사용한 간 질환의 조합 치료 Download PDF

Info

Publication number
KR20220121838A
KR20220121838A KR1020227024756A KR20227024756A KR20220121838A KR 20220121838 A KR20220121838 A KR 20220121838A KR 1020227024756 A KR1020227024756 A KR 1020227024756A KR 20227024756 A KR20227024756 A KR 20227024756A KR 20220121838 A KR20220121838 A KR 20220121838A
Authority
KR
South Korea
Prior art keywords
liver
liver disease
compound
disorder
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227024756A
Other languages
English (en)
Korean (ko)
Inventor
크레이그 앤더슨
크리스토퍼 베일리
아비루프 보스
야곱 차
니콜 쿠퍼
대런 핀켈스타인
린다 그린바움
조안 헐
수잔 커클랜드
카트리나 레프테리스
마우렌 라일리
피터 타르사
친웨이크 우코마두
Original Assignee
노파르티스 아게
플라이언트 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게, 플라이언트 테라퓨틱스, 인크. filed Critical 노파르티스 아게
Publication of KR20220121838A publication Critical patent/KR20220121838A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227024756A 2019-12-20 2020-12-18 인테그린 억제제를 사용한 간 질환의 조합 치료 Pending KR20220121838A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951615P 2019-12-20 2019-12-20
US62/951,615 2019-12-20
PCT/US2020/066079 WO2021127483A1 (en) 2019-12-20 2020-12-18 Combination treatment of liver diseases using integrin inhibitors

Publications (1)

Publication Number Publication Date
KR20220121838A true KR20220121838A (ko) 2022-09-01

Family

ID=74186956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227024756A Pending KR20220121838A (ko) 2019-12-20 2020-12-18 인테그린 억제제를 사용한 간 질환의 조합 치료

Country Status (11)

Country Link
US (1) US20230055657A1 (enExample)
EP (1) EP4076455A1 (enExample)
JP (1) JP2023507387A (enExample)
KR (1) KR20220121838A (enExample)
CN (1) CN114929219A (enExample)
AR (1) AR120859A1 (enExample)
AU (1) AU2020405182B2 (enExample)
CA (1) CA3165000A1 (enExample)
IL (1) IL293895A (enExample)
TW (1) TW202135812A (enExample)
WO (1) WO2021127483A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220220206A1 (en) * 2019-05-20 2022-07-14 Mayo Foundation For Medical Education And Research Treating chronic liver disease
US20230060422A1 (en) * 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP3509590A4 (en) * 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
RU2019110780A (ru) * 2016-09-14 2020-10-15 Новартис Аг Комбинация агонистов fxr
TWI841573B (zh) * 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN118852054A (zh) * 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途

Also Published As

Publication number Publication date
AU2020405182B2 (en) 2024-03-14
EP4076455A1 (en) 2022-10-26
CA3165000A1 (en) 2021-06-24
JP2023507387A (ja) 2023-02-22
AU2020405182A1 (en) 2022-07-07
IL293895A (en) 2022-08-01
US20230055657A1 (en) 2023-02-23
CN114929219A (zh) 2022-08-19
TW202135812A (zh) 2021-10-01
AR120859A1 (es) 2022-03-23
WO2021127483A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
WO2024148104A1 (en) Combination therapy of apelin receptor agonist and glp-1 receptor agonist for treating a disease or condition associated with weight gain
US20220265619A1 (en) Combination treatment of liver diseases using fxr agonists
US20230060422A1 (en) Combination treatment of liver diseases using integrin inhibitors
KR20190062501A (ko) 섬유증, 간경화 질환 또는 질병을 치료 또는 예방하기 위한 fxr 작용제를 포함하는 조합 조성물
KR102218498B1 (ko) Fxr 작용제들의 조합물
US20200276178A1 (en) Combinations comprising fxr agonists
US11052069B2 (en) Regimes of FXR agonists
KR20220121838A (ko) 인테그린 억제제를 사용한 간 질환의 조합 치료
JP7194745B2 (ja) チオフェン［３，２－ｄ］ピリミジン－４－ケトン系化合物の医薬用途
JP2022548617A (ja) Ｆｘｒアゴニストを含む処置
WO2025213190A1 (en) Methods of treating a disease or condition associated with weight gain

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902